Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Bone material strength increases 1 year after gastric bypass

29 Oct 2019

At 1 year following Roux-en-Y gastric bypass (RYGB), patients may see an improvement in bone material strength despite an increase in bone turnover and a decline in areal bone mineral density (aBMD), a recent study has found. While this trend is similar in those with and without type 2 diabetes (T2D), improved glucose control is associated with increased bone material strength among T2D patients.

Researchers looked at 34 participants who underwent RYGB, among whom 13 had T2D (median duration, 4 years). Of the patients with T2D, eight (62 percent) were treated with one or more oral glucose-lowering drugs and one received both insulin and oral antidiabetic drug.

Preoperative bone material strength index (BMSi) had an inverse association with body mass index (BMI; p=0.010), and this association remained significant despite controlling for age and gender. One year after RYGB, the participants shed a mean of 33.9 kg in weight and 48.7 percent in total body fat and increased physical activity. Vitamin D levels remained unchanged, and only one patient with T2D was in remission.

Specifically, BMSi increased from 78.1 preoperatively to 82.0 at 1 year after RYGB, corresponding to an increase of 4.0 in absolute units or 6.3 percent (p=0.037). The increase was comparable in participants with and without T2D.

In patients with T2D, a greater decrease in HbA1c correlated with a larger increase in BMSi (p=0.019). Bone turnover markers, namely CTX-1 and PINP, increased by 195.1 percent and 109.5 percent, respectively.

Meanwhile, aBMD decreased by 3.9 percent in the lumbar spine, 8.2 percent in the femoral neck, 11.6 percent in total hip and 9.4 percent in total body.

The present data support the hypothesis that higher BMI is associated with reduced bone material strength, as well as show that surgically induced weight loss exerts a positive effect on bone quality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.